chr7-116695757-A-T
Variant names:
Variant summary
Our verdict is Benign. The variant received -12 ACMG points: 0P and 12B. BP4_StrongBA1
The NM_000245.4(MET):c.-14-3314A>T variant causes a intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0477 in 490,252 control chromosomes in the GnomAD database, including 761 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as not provided (no stars).
Frequency
Genomes: 𝑓 0.059 ( 341 hom., cov: 32)
Exomes 𝑓: 0.043 ( 420 hom. )
Consequence
MET
NM_000245.4 intron
NM_000245.4 intron
Scores
1
1
11
Clinical Significance
Conservation
PhyloP100: -0.325
Publications
12 publications found
Genes affected
MET (HGNC:7029): (MET proto-oncogene, receptor tyrosine kinase) This gene encodes a member of the receptor tyrosine kinase family of proteins and the product of the proto-oncogene MET. The encoded preproprotein is proteolytically processed to generate alpha and beta subunits that are linked via disulfide bonds to form the mature receptor. Further processing of the beta subunit results in the formation of the M10 peptide, which has been shown to reduce lung fibrosis. Binding of its ligand, hepatocyte growth factor, induces dimerization and activation of the receptor, which plays a role in cellular survival, embryogenesis, and cellular migration and invasion. Mutations in this gene are associated with papillary renal cell carcinoma, hepatocellular carcinoma, and various head and neck cancers. Amplification and overexpression of this gene are also associated with multiple human cancers. [provided by RefSeq, May 2016]
COMETT (HGNC:51196): (cytosolic oncogenic antisense to MET transcript) This gene encodes a natural antisense transcript highly expressed in papillary thyroid carcinomas harboring BRAF V600E mutation or RET gene rearrangements. This lncRNA induces the downstream MAPK pathway and is part of a co-expression network including different oncogenes belonging to the MAPK and PI3H/AKT pathways. In thyroid carcinomas, this gene has oncogenic properties associated with increased proliferation and drug resistance. [provided by RefSeq, Jan 2020]
Genome browser will be placed here
ACMG classification
Classification was made for transcript
Our verdict: Benign. The variant received -12 ACMG points.
BP4
Computational evidence support a benign effect (MetaRNN=0.0027790964).
BA1
GnomAd4 highest subpopulation (AFR) allele frequency at 95% confidence interval = 0.0937 is higher than 0.05.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
MET | NM_000245.4 | c.-14-3314A>T | intron_variant | Intron 1 of 20 | ENST00000397752.8 | NP_000236.2 |
Ensembl
Frequencies
GnomAD3 genomes AF: 0.0586 AC: 8911AN: 152164Hom.: 335 Cov.: 32 show subpopulations
GnomAD3 genomes
AF:
AC:
8911
AN:
152164
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD2 exomes AF: 0.0475 AC: 6981AN: 147110 AF XY: 0.0460 show subpopulations
GnomAD2 exomes
AF:
AC:
6981
AN:
147110
AF XY:
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0428 AC: 14458AN: 337970Hom.: 420 Cov.: 0 AF XY: 0.0426 AC XY: 8029AN XY: 188650 show subpopulations
GnomAD4 exome
AF:
AC:
14458
AN:
337970
Hom.:
Cov.:
0
AF XY:
AC XY:
8029
AN XY:
188650
show subpopulations
African (AFR)
AF:
AC:
927
AN:
9206
American (AMR)
AF:
AC:
2078
AN:
27462
Ashkenazi Jewish (ASJ)
AF:
AC:
296
AN:
12148
East Asian (EAS)
AF:
AC:
944
AN:
14170
South Asian (SAS)
AF:
AC:
2324
AN:
59198
European-Finnish (FIN)
AF:
AC:
278
AN:
26588
Middle Eastern (MID)
AF:
AC:
149
AN:
2910
European-Non Finnish (NFE)
AF:
AC:
6749
AN:
170266
Other (OTH)
AF:
AC:
713
AN:
16022
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.463
Heterozygous variant carriers
0
551
1102
1653
2204
2755
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
GnomAD4 genome AF: 0.0587 AC: 8944AN: 152282Hom.: 341 Cov.: 32 AF XY: 0.0581 AC XY: 4323AN XY: 74456 show subpopulations
GnomAD4 genome
AF:
AC:
8944
AN:
152282
Hom.:
Cov.:
32
AF XY:
AC XY:
4323
AN XY:
74456
show subpopulations
African (AFR)
AF:
AC:
3997
AN:
41544
American (AMR)
AF:
AC:
1215
AN:
15300
Ashkenazi Jewish (ASJ)
AF:
AC:
86
AN:
3470
East Asian (EAS)
AF:
AC:
361
AN:
5180
South Asian (SAS)
AF:
AC:
217
AN:
4824
European-Finnish (FIN)
AF:
AC:
99
AN:
10624
Middle Eastern (MID)
AF:
AC:
23
AN:
294
European-Non Finnish (NFE)
AF:
AC:
2783
AN:
68020
Other (OTH)
AF:
AC:
116
AN:
2114
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.502
Heterozygous variant carriers
0
429
859
1288
1718
2147
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
Alfa
AF:
Hom.:
Bravo
AF:
TwinsUK
AF:
AC:
175
ALSPAC
AF:
AC:
172
ExAC
AF:
AC:
687
Asia WGS
AF:
AC:
247
AN:
3478
ClinVar
Significance: not provided
Submissions summary: Other:1
Revision: no classification provided
LINK: link
Submissions by phenotype
not specified Other:1
Sep 19, 2013
ITMI
Significance:not provided
Review Status:no classification provided
Collection Method:reference population
- -
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_addAF
Benign
T
BayesDel_noAF
Benign
DANN
Benign
Eigen
Benign
Eigen_PC
Benign
FATHMM_MKL
Benign
N
LIST_S2
Uncertain
D
MetaRNN
Benign
T
MetaSVM
Benign
T
PhyloP100
PROVEAN
Benign
N
REVEL
Benign
Sift
Pathogenic
D
MutPred
Loss of MoRF binding (P = 0.148);
ClinPred
T
GERP RS
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at
Publications
You must be logged in to view publications. This limit was set because tens of millions (!) of queries from AI bots are generated daily.